Q-omics provides the consensus-scored H2AZP6 profile across patient tissues and cancer cell-line models. H2AZP6 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, H2AZP6 is differentially expressed in 5, with the highest sampling consensus in STAD. Additionally, H2AZP6 RNA expression shows 6,538 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, and STAD as cancer lineages where H2AZP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H2AZP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H2AZP6 survival associations across molecular data types. H2AZP6 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H2AZP6 RNA expression–survival associations across cancer types. High H2AZP6 expression shows unfavorable associations in LIHC, UVM, CHOL, ACC, THYM and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for H2AZP6 RNA expression.
This table summarizes H2AZP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for H2AZP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H2AZP6 shows lower tumor expression in KICH, THCA and HNSC and higher tumor expression in STAD and ESCA. The STAD box plot shows higher H2AZP6 RNA expression in tumor versus normal tissue (log2 FC = +0.338, t-test p < 0.001).
This table shows molecular features associated with H2AZP6 in patient tissues and cancer cell lines. In patient samples, H2AZP6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
